Blog

Jan 11, 2025, 10:05

Rémy Duléry: T cell malignancies after CAR T cell therapy in the DESCAR-T registry

Rémy Duléry, Professor of Hematology at Sorbonne University, Saint-Antoine Hospital in Paris, shared on X:

“Happy to share our work published in Nature Medicine

We analyzed 3,066 patients from the French DESCAR-T registry who received CARTcell therapy. Our findings indicate a very low risk of T-cell malignancy after CAR T-cell therapy: only 1 case (0.03%).”

T cell malignancies after CAR T cell therapy in the DESCAR-T registry | Nature Medicine

Authors: Remy Dulery, Vincent Guiraud, Sylvain Choquet, Catherine Thieblemont, Emmanuel Bachy, Stéphane Barete, Ève Todesco, Bertrand Arnulf, Nicolas Boissel, André Baruchel, Jacques-Olivier Bay, Steven Le Gouill and Roch Houot.

Rémy Duléry: T cell malignancies after CAR T cell therapy in the DESCAR-T registry

André Baruchel Bertrand Arnulf cancer Catherine Thieblemont Emmanuel Bachy Ève Todesco Jacques-Olivier Bay Nicolas Boissel OncoDaily Oncology Rémy Duléry Stéphane Barete Steven Le Gouill and Roch Houot Sylvain Choquet Vincent Guiraud

ACT for Children: Tackling Inequities in Childhood Cancer Through Unique Global Collaboration

Richard Gere and Alejandra Gere to Join Second Global OncoThon on February 15 for Fight Against Childhood Cancer

Mesothelioma Guideline Updates from ASCO 2024: Key Advances in Diagnosis and Treatment

Oncologist Near Me - Lynn Schuchter: A Pioneering Leader in Cancer Care and Melanoma Research

NIH lowered the maximum indirect cost rate research institutions can charge the government to 15%